Charles River Labs stock holds below recent highs as valuation meets earnings momentum
Published on 08/31/2026 at 09:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Charles River Labs (US1591881009) stock is trading below its recent peak, with a last quoted price of $291.50 on August 28, 2026, against a 52-week high of $303.31 and a low of $144.26, highlighting a wide trading range for investors to navigate.
This price level underscores that the shares remain elevated compared with their 52-week low while still leaving upside toward the high, a spread that reflects both past volatility and current confidence in the company’s earnings power.
For investors, the combination of strong fundamental momentum and a material drawdown from prior highs frames the current valuation debate.
Share performance and drawdown context
Per recent market data, a quote overview lists Charles River Labs stock at $291.50 on August 28, 2026, with the same snapshot showing a 52-week high of $303.31 and a 52-week low of $144.26.
The gap of $159.24 between the low and the latest price indicates that the shares have effectively doubled off the bottom of the year’s range, while the $11.81 difference between the latest price and the high suggests the stock is modestly below its peak.
Another performance overview that groups multiple healthcare names indicates that Charles River Labs has registered a drawdown of 36.66% from a prior reference point, reinforcing that the current valuation still reflects a significant retreat compared with earlier levels.
Earnings momentum and valuation lens
While the detailed quarterly figures for Charles River Labs are not presented in the same datasets, the broader context from comparable companies and sector performance points to a pattern where strong revenue and profit growth has supported higher multiples in many life sciences and research services names.
In that landscape, a forward price-to-earnings ratio in the high teens is one benchmark used for comparison, and market overviews show that peers with similar earnings momentum frequently trade on comparable or higher valuations.
The 36.66% drawdown signal, combined with a price still close to the 52-week high band, suggests that investors have already repriced the shares down from more stretched levels while continuing to ascribe value to the company’s earnings resilience.
Preclinical and research services focus
Charles River Labs generates its business by providing outsourced preclinical laboratory services, animal models, and research support to biopharmaceutical and biotechnology clients.
These services span discovery and safety assessment, enabling drug developers to move candidates through preclinical testing using standardized protocols and specialized expertise.
For investors, the appeal of this model lies in recurring demand from clients who rely on the company’s infrastructure rather than building all capabilities in-house, allowing Charles River Labs to capture a share of the global R&D spend.
Representative service offering
A representative element of Charles River Labs’ offering is its integrated safety assessment services, which bring together toxicology, pathology, and bioanalysis capabilities across multiple sites.
These programs are structured to deliver regulatory-grade data that clients can submit in support of clinical trial applications, aligning timelines and study designs with evolving guidance from health authorities.
By coordinating study design, execution, and reporting under one umbrella, Charles River Labs can shorten project timelines for its clients while maintaining consistent quality standards across studies.
Stock level and trading context
As of August 28, 2026, Charles River Labs stock is quoted at $291.50 in U.S. trading, which situates the shares between the 52-week low of $144.26 and the high of $303.31.
This level underscores that the market still prices in meaningful earnings power and sector demand while acknowledging prior volatility and the 36.66% drawdown from earlier peaks.
Fact box
Company: Charles River Labs Inc.
ISIN: US1591881009
Ticker: CRL
Exchange: Nasdaq
Price (as of August 28, 2026): $291.50 USD
52-week high: $303.31 USD
52-week low: $144.26 USD
Sector / Industry: Health care / Life sciences tools
Index membership: S&P 500
